Literature DB >> 15805265

p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression.

Jean-Francois Geay1, Dorothée Buet, Yanyan Zhang, Adlen Foudi, Peggy Jarrier, Magali Berthebaud, Ali G Turhan, William Vainchenker, Fawzia Louache.   

Abstract

It has been shown that p210(BCR-ABL) significantly impairs CXCR4 signaling. We report here that the migratory response to SDF-1 was profoundly altered in blast crisis, whereas chronic-phase CD34(+) cells migrated normally to this chemokine. This migratory defect was associated with a low CXCR4 membrane expression. In vitro STI-571 treatment of CD34(+) cells from patients in blast crisis markedly increased the CXCR4 transcript and CXCR4 membrane expression. Because p210(BCR-ABL) frequently increases with disease progression, we determined the effects of high and low p210(BCR-ABL) expression on CXCR4 protein in the granulocyte macrophage colony-stimulating factor-dependent human cell line MO7e. p210(BCR-ABL) expression distinctly alters CXCR4 protein through two different mechanisms depending on its expression level. At low expression, a signaling defect was detected with no modification of CXCR4 expression. However, higher p210(BCR-ABL) expression induced a marked down-regulation of CXCR4 that is related to its decreased transcription. The effect of p210(BCR-ABL) required its tyrosine kinase activity. Collectively, these data indicate that p210(BCR-ABL) could affect CXCR4 by more than one mechanism and suggest that down-regulation of CXCR4 may have important implications in chronic myelogenous leukemia pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15805265     DOI: 10.1158/0008-5472.CAN-04-2152

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Inhibition of class II phosphoinositide 3-kinase gamma expression by p185(Bcr-Abl) contributes to impaired chemotaxis and aberrant homing of leukemic cells.

Authors:  Weidong Yu; Xiaolin Sun; Hongxing Tang; Yunxia Tao; Zonghan Dai
Journal:  Leuk Lymphoma       Date:  2010-06

2.  Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis.

Authors:  Fabrizio Vianello; Federica Villanova; Veronica Tisato; Stefania Lymperi; Ka-Kei Ho; Ana R Gomes; David Marin; Dominique Bonnet; Jane Apperley; Eric W-F Lam; Francesco Dazzi
Journal:  Haematologica       Date:  2010-02-23       Impact factor: 9.941

3.  Integrin inhibition through Lyn-dependent cross talk from CXCR4 chemokine receptors in normal human CD34+ marrow cells.

Authors:  Yuji Nakata; Brian Tomkowicz; Alan M Gewirtz; Andrzej Ptasznik
Journal:  Blood       Date:  2006-02-07       Impact factor: 22.113

Review 4.  Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.

Authors:  Marina Konopleva; Yoko Tabe; Zhihong Zeng; Michael Andreeff
Journal:  Drug Resist Updat       Date:  2009-07-25       Impact factor: 18.500

Review 5.  Integration of hypoxic HIF-α signaling in blood cancers.

Authors:  L Schito; S Rey; M Konopleva
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

6.  Stromal cell-derived factor-1 chemokine gene variant in blood donors and chronic myelogenous leukemia patients.

Authors:  Carlos Eduardo Coral de Oliveira; Gabriela Gonçalves de Oliveira Cavassin; Aparecida de Lourdes Perim; Thiago Franco Nasser; Karen Brajão de Oliveira; Maria Helena Pelegrinelli Fungaro; Juliana Laino do Val Carneiro; Maria Angelica Ehara Watanabe
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

Review 7.  The bone marrow microenvironment and leukemia: biology and therapeutic targeting.

Authors:  Edward Allan R Sison; Patrick Brown
Journal:  Expert Rev Hematol       Date:  2011-06       Impact factor: 2.929

8.  Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease.

Authors:  Anna Rita Migliaccio; Fabrizio Martelli; Maria Verrucci; Giovanni Migliaccio; Alessandro Maria Vannucchi; Hongyu Ni; Mingjiang Xu; Yi Jiang; Betty Nakamoto; Thalia Papayannopoulou; Ronald Hoffman
Journal:  Exp Hematol       Date:  2008-02       Impact factor: 3.084

9.  Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.

Authors:  Anupriya Agarwal; Angela G Fleischman; Curtis L Petersen; Ryan MacKenzie; Samuel Luty; Marc Loriaux; Brian J Druker; Randall L Woltjer; Michael W Deininger
Journal:  Blood       Date:  2012-08-13       Impact factor: 22.113

10.  Pertussis toxin signals through the TCR to initiate cross-desensitization of the chemokine receptor CXCR4.

Authors:  Olivia D Schneider; Alison A Weiss; William E Miller
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.